Dysfunctional Lipid-Induced Secretion of Glucagon-Like Peptide-2(GLP-2), but Not of Incretins Glucagon-Like Peptide-1(GLP-1)/Glucose-Dependent Insulinotropic Polypeptide(GIP), Promotes Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) Onset and Progression Through Gut Barrier Disruption and Endotoxemia

Giovanni Musso; Silvia Pinach; Alberto Mella; Franco De Michieli; Anna Calabrese; Deborah Trifiro; Giovanna Petrangolini; Maurizio Cassader; Filippo Mariano; Roberto Gambino

doi:10.1002/mco2.70323

MedComm ›› 2026, Vol. 7 ›› Issue (4) :e70323 DOI: 10.1002/mco2.70323

LETTER

Dysfunctional Lipid-Induced Secretion of Glucagon-Like Peptide-2(GLP-2), but Not of Incretins Glucagon-Like Peptide-1(GLP-1)/Glucose-Dependent Insulinotropic Polypeptide(GIP), Promotes Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) Onset and Progression Through Gut Barrier Disruption and Endotoxemia

Author information +

History +

PDF (594KB)

Keywords

endotoxemia / intestinal barrier / LPS / NF-kB / postprandial / steatohepatitis

Cite this article

Download citation ▾

Giovanni Musso, Silvia Pinach, Alberto Mella, Franco De Michieli, Anna Calabrese, Deborah Trifiro, Giovanna Petrangolini, Maurizio Cassader, Filippo Mariano, Roberto Gambino. Dysfunctional Lipid-Induced Secretion of Glucagon-Like Peptide-2(GLP-2), but Not of Incretins Glucagon-Like Peptide-1(GLP-1)/Glucose-Dependent Insulinotropic Polypeptide(GIP), Promotes Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) Onset and Progression Through Gut Barrier Disruption and Endotoxemia. MedComm, 2026, 7 (4) : e70323 DOI:10.1002/mco2.70323

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	M. E. Rinella, B. A. Neuschwander-Tetri, M. S. Siddiqui, et al., “AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease,” Hepatology 77 (2023): 1797–1835.

[2]	M. Carmiel-Haggai, A. I. Cederbaum, and N. Nieto, “A High-Fat Diet Leads to the Progression of Non-alcoholic Fatty Liver Disease in Obese Rats,” FASEB Journal 19 (2005): 136–138.

[3]	E. Sasso, L. Baticic, and V. Sotosek, “Postprandial Dysmetabolism and Its Medical Implications,” Life 13 (2023): 2317.

[4]	G. D. Kolovou, G. F. Watts, D. P. Mikhailidis, et al., “Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text,” Current Vascular Pharmacology 17 (2019): 498–514.

[5]	E. Á. Hernández, S. Kahl, A. Seelig, et al., “Acute Dietary Fat Intake Initiates Alterations in Energy Metabolism and Insulin Resistance,” Journal of Clinical Investigation 127 (2017): 695–708.

[6]	B. Begaye, K. L. Vinales, T. Hollstein, et al., “Impaired Metabolic Flexibility to High-Fat Overfeeding Predicts Future Weight Gain in Healthy Adults,” Diabetes 69 (2020): 181–192.

[7]	M. Takikawa, Y. Kurimoto, and T. Tsuda, “Curcumin Stimulates Glucagon-Like Peptide-1 Secretion in GLUTag Cells via Ca2+/Calmodulin-dependent Kinase II Activation,” Biochemical and Biophysical Research Communications 435 (2013): 165–170.

[8]	N. Harada, M. Okuyama, Y. Teraoka, et al., “Identification of G Protein-Coupled Receptor 55 (GPR55) as a Target of Curcumin,” npj Science of Food 6 (2022): 4.

[9]	G. Musso, S. Pinach, F. Mariano, et al., “Effect of Phospholipid Curcumin Meriva on Liver Histology and Kidney Disease in Nonalcoholic Steatohepatitis: A Randomized, Double-blind, Placebo-controlled Trial,” Hepatology 81 (2025): 560–575.

[10]	Q. Ye, B. Zou, Y. H. Yeo, et al., “Global Prevalence, Incidence, and Outcomes of Non-obese or Lean Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis,” Lancet Gastroenterol Hepatol 5 (2020): 739–752.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.